Senses Disorder TRIZ Cases

This case uses Anc80 AAV vectors and tailored promoters to improve local anti-VEGF delivery for vestibular schwannoma.

This case examines PEGylated CBS dosing for homocysteine reduction, longer circulation, and fewer dietary restrictions in CBSDH.

Topical esterified anti-inflammatory lipid mediators support tear-film stability while reducing discomfort and easing dry eye inflammation.

PLGA nanospheres and implants provide controlled ocular release, maintaining therapeutic concentrations while reducing liver toxicity risks.

This case uses a cycloolefin polymer barrel to limit silicone oil contamination, particle formation, and storage instability.

Novel fused-ring heteroaryl compounds target RIPK1 selectively, helping limit necroptosis and inflammation across disease applications.

N-Desmethyl ruboxistaurin maintains GSK3 inhibition with lower QT risk.

This ophthalmic composition uses 40,000–70,000 MW chondroitin sulfate to reduce eye dryness and improve contact lens compatibility.

This case replaces animal-tissue extraction with recombinant E. coli expression for more processable type VIII collagen.

Urolithins address defective protein and organelle accumulation by increasing autophagy and supporting cellular health.

This case combines anti-CD14 and anti-VEGF therapies to address ocular fibrosis and neovascularization linked to vision loss.

Four MBP-derived peptides bind diverse MHC class II haplotypes, promoting immune tolerance to prevent or treat uveitis.

A non-integrating episomal vector delivers dCas9/gRNA to activate haploinsufficient genes while avoiding permanent genome modification.

This case uses intravitreal vasodilators to grow capillaries and improve blood supply to ocular tissue in glaucoma.

A protein-containing wash solution and centrifugation remove culture-derived components while preserving corneal endothelial cell recovery.

This case combines BHA and BHT to preserve omega-3 oil stability in artificial tears and dry-eye ophthalmic compositions.

This case uses alpha1-blocker eyedrops to reduce refractive power and axial elongation without complex medical intervention.

A semi-permeable capsule releases biologically active molecules locally, maintaining therapeutic levels without long-term immunosuppression.

This case extracts HGF, VEGF, TIMP-1, Serpin E1, and Pentraxin-3 to promote limbal regeneration while reducing immune-rejection concerns.

Engineered hemichannels and vesicles use calcium response and esterase cleavage to control delivery of fragile biologic cargo.

AAV delivery combines VEGF-A and ANG-2 targeting to reduce repeat eye injections.

rAAV constructs enable local anti-VEGF expression where systemic delivery may fall short.

This case uses amino acid changes in AAV2 capsids to broaden retinal-region delivery while maintaining high nucleic acid expression.

Notch1/Notch4 EGF repeats 10-14 fused to Fc block DLL4 and JAG1, avoiding γ-secretase inhibition while easing production.

This case replaces HDR with NHEJ-based HITI to support mutation-independent correction and stable gene expression in differentiated cells.

A dilute peptide formulation uses low EDTA, citrate, and optional tyloxapol to preserve stability while reducing preservatives.

This case uses rAAV capsids and tissue-specific promoters to improve local anti-VEGF delivery for vestibular schwannoma.

Outer hair cell-specific promoters guide AAV delivery of therapeutic polynucleotides where amplification cannot address hair cell damage.

This case shows how azepine-fused ring structures improve RIPK1 inhibitory potency while preserving selectivity over other kinases.

This case uses PspC-derived protein fragments to stabilize CFH, strengthen C3b/C3d binding, and limit complement amplification.

This case uses a p62 ligand to activate mTOR-independent autophagy and route misfolded aggregates to autophagosomes.

IGF1 and STAT3 medium directly induces iPS cells into corneal endothelial substitutes.

This case uses CDR-defined recombinant antibodies to bind human IL-33 and block its signaling in inflammatory diseases.

This case combines PDE5 inhibition with nitrate-based NO release to raise cGMP and address limited potency versus sildenafil.

Pupil and accommodation measurements estimate atropine concentration for personalized myopia treatment with fewer side effects.

Non-aqueous emulsions protect therapeutic proteins during microgel encapsulation.

This case pairs APX inhibitors with second agents to selectively block APE1/Ref-1 redox signaling in retinal diseases.

This case uses a 3-phenylisoxazole derivative to activate autophagy, clear A2E, and protect retinal cells from blue-light damage.

Embryoid body-free culture yields over 99% pure RPE cells at scale.

STRC, Slc26a5, otof, Sox10, Ngfr, and Dnah5 promoters focus viral gene expression in ear cells, limiting brain-cell exposure.

Developmental transcription factors delivered by AAV reprogram Müller glia, addressing inflammation-limited retinal regeneration.

This case uses intranasal insulin to reach retinal and CNS tissues, addressing neurodegeneration while limiting systemic side effects.

This staged pluripotent stem cell process removes embryoid bodies and supports scalable RPE production above 99% purity for clinical use.

This case uses Anelloviridae capsids to deliver genetic material with low immunogenicity and infrequent genome integration.

This case develops humanized anti-CD38 antibodies that kill CD38+ cancer cells through apoptosis, ADCC, and CDC without stroma.

This case combines suspending agents, buffers, and tonicity control for sterilizable, prolonged delivery to target tissues.

Muscarinic antagonists reduce cerumen production and help prevent ear canal blockage.

This case develops cyano-substituted pyridine and pyrimidine compounds to selectively inhibit FGFR4, including mutant FGFR4V550L.

Combining IL-11 signalling and angiogenesis antagonists addresses limited anti-VEGF effectiveness in eye fibrosis treatment.

This case uses a Formula 2 carbamate compound to address disease progression, nerve damage, and retinal ganglion cell protection.